LDS/Medical Tests/Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue

Lung Cancer, RET (10q11) Rearrangement, FISH, Tissue

Rearrangement of the RET gene, also known as RET/PTC rearrangement, is the most common genetic alteration identified in papillary thyroid carcinomas. It is formed by fusion of the tyrosine kinase domain of RET to genes located on different chromosomes. The genes fused with RET are constitutively expressed in thyroid follicular cells and drive the expression of the chimeric RET/PTC oncogene. RET/PTC gene fusion is detected in 5-40% of papillary thyroid carcinoma and found rarely in other types of thyroid lesions.

There are at least13 different types of RET/PTC rearrangements among which RET/PTC1 and RET/PTC3 are most frequent ones. RET/PTC1 is formed by fusion with the CCDC6 or H4 gene, and RET/PTC3 by fusion with the ELE1 gene. RET/PTC1 appears to be the most common rearrangement in spontaneous adult and childhood thyroid cancers, whereas both RET/PTC1 and RET/PTC3 rearrangements are observed with a high prevalence in radiation-induced thyroid cancers. Other variant rearrangements have been isolated just in rare cases.

Abnormalities of the RET proto-oncogene at chromosome 10q11 have been identified as the causative genetic abnormality lung adenocarcinomas. Patients with tumors harboring RET rearrangements may benefit from RET kinase inhibitors, but the clinical benefits of the inhibitor has not yet been clarified. Identifying RET gene rearrangements in patients with late-stage, lung adenocarcinomas that are negative for EGFR mutations and ALK rearrangements is used for therapy selection and monitoring.

Lung cancer is the leading cause of cancer mortality in developed countries. The discovery of a variety of genetic alterations in non-small-cell lung cancer (NSCLC) has enabled the use of targeted therapy such as the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, for NSCLC with ALK rearrangements and EGFR mutations, respectively.

  • Aid in the diagnosis of papillary thyroid carcinoma
  • Identifying RET gene rearrangements in patients with late-stage, lung adenocarcinomas that are negative for EGFR mutations and ALK rearrangements
  • Confirmatory test for papillary thyroid carcinoma when the conventional cytology yields inconclusive results
  • Therapy selection and disease management

Negative:

  • No rearrangement of the RET gene was identified.

Positive:

  • Abnormal results indicate rearrangement of the RET gene, indicating tath Lung adenocarcinomas with RET rearrangements may be sensitive to directed RET kinase inhibitors

No rearrangement of the RET gene was identified

Fluorescence In Situ Hybridization (FISH).

Formalin-fixed paraffin embedded (FFPE) tissue block, fine needle aspiration (FNA), frozen tissue.

Stability

FFPE samples are stable at room temperature for longer. 

Lung biopsy, KRAS, BRAF, EGFR mutation analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login